Time | Title | Speaker |
---|---|---|
08:50-09:00 | Welcome Ceremony | |
´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ȸÀå Àλç | ±èÇѼö ȸÀå | |
´ëÇѳ»°úÀÇ»çȸ ȸÀå Ãà»ç | ¹Ú±ÙÅ ȸÀå | |
09:00-10:10 | Session I. Current Update 2021 | ÁÂÀå: ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ±ÇÁØ °í¹® ÀüºÏ³»°úÀÇ»çȸ ½ÅºÀÁÖ È¸Àå |
09:00-09:20 | Hypertension step up - BP variability (HBPM, ABPM, cuffless BP monitoring), 2020 ISH °¡À̵å¶óÀÎreview | À̹«¿ë (µ¿±¹ÀÇ´ë) |
09:20-09:40 | °í¿ë·® ½ºÅ¸Æ¾°ú ¹ÝÀÀÇÏÁö ¾Ê´Â ÀÌ»óÁöÁúÇ÷Áõ ȯÀÚ Ä¡·á-PCSK-9 ¾ïÁ¦Á¦¿Í Evinacumab (ANGPTL3 monoclonal antibody) | È«¼øÁØ (°í·ÁÀÇ´ë) |
09:40-10:00 | ½É¹æ¼¼µ¿ ȯÀÚ, °ú¿¬ 2021³â¿¡µµ Rate control¸¸ Çϸé ÃæºÐÇÒ±î? | À̱âÈ« (Àü³²ÀÇ´ë) |
10:10-12:00 | Session II. Live interactive session with Experts! | ÁÂÀå: ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ Á¤³²½Ä °í¹® |
Live Talk & Talk, ÀÌ·±Áú¹® Çصµ µÇ³ª¿ä? | Panel: ÀÌ»ó (½º¸¶Æ®³»°ú) ½ÅÀÌö (´ë±¸21¼¼±â³»°ú) |
|
10:10-10:20 | °¡½¿ÀÌ ¾ÆÇ ȯÀÚ, ¾ðÁ¦, ´©±¸¸¦ Àü¿ø½Ãų±î? | ÀÌöȯ (¿ï»êÀÇ´ë) |
10:20-10:50 | ¾ÈÁ¤Çü Çé½ÉÁõ(chronic coronary syndrome)ȯÀÚ, ÀûÀýÇÏ°Ô Ä¡·áÇϱâ | ÀÌöȯ (¿ï»êÀÇ´ë) |
10:50-11:15 | Coronary CT, coronary calcium score ¿Ã¹Ù¸¥ Çؼ®¹ý | Á¶Àͼº (¿¬¼¼ÀÇ´ë) |
11:15-11:40 | ¼ö¼ú Àü consult, ÀÌ·¸°Ô ´ë´äÇÏÀÚ! | ¹èÀåȯ (ÃæºÏÀÇ´ë) |
11:40-12:00 | ¼ö¼ú Àü, ÈÄ Ç×ÀÀ°íÁ¦ ÀÌ·¸°Ô Á¶ÀýÇÏÀÚ! | ¹èÀåȯ (ÃæºÏÀÇ´ë) |
Time | Title | Speaker |
---|---|---|
12:00-13:00 | Luncheon symposium | ¡¡ |
12:00-12:20 | Cardiorenal disease continuum; CV risk factor to the death | Á¶»óÈ£ (ÇѸ²ÀÇ´ë) |
12:20-12:40 | The management of hypertension with Fimasartan in Korea | ½Åµ¿±Ý (ÇѸ²ÀÇ´ë) |
13:00-13:40 | State of the Art : Çѱ¹ ½ÉÃÊÀ½ÆÄÀÇ ¾îÁ¦¿Í ¿À´Ã, ±×¸®°í ¹Ì·¡ | Á¤³²½Ä (Çʸ޵𽺳»°ú) |
13:40-15:20 | Session III. Systemic disease & Heart | ÁÂÀå: ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ±èÁø±¸ °¨»ç ÀÎõ½Ã³»°úÀÇ»çȸ °ûÇöö ȸÀå |
Live Talk & Talk ´ç´¢º´°ú Ç÷°ü | Panel:ÃÖ¿µÁÖ (´ç´ç³»°ú) ¿À¹Î¼® (Áß¾Óº¸Èƺ´¿ø) |
|
13:40-14:10 | ´ç´¢º´ ȯÀÚ, ½ÉÇ÷°ü ÁúȯÀ» ¿¹¹æÇÏ·Á¸é ¾î¶»°Ô ÇØ¾ß ÇÒ±î? | ±ÇÇõ»ó (°¡Å縯ÀÇ´ë) |
14:10-14:40 | GLP-1 agonist or SGLT2 antagonist, which should be considered 1st for the heart? | ¹ÚÁ¤Çö (ÀÎÁ¦ÀÇ´ë) |
14:40-15:00 | ´ç´¢º´ ȯÀÚ°¡ Àß °É¸®´Â ½ÉÇ÷°üÁúȯ ÃÑÁ¤¸® | ½Å¼ºÈñ (ÀÎÇÏÀÇ´ë) |
15:00-15:20 | ´ç´¢º´¼º ¸»ÃÊ ½Å°æº´Áõ, ¾ðÁ¦ ÀǽÉÇÏ°í ¾î¶»°Ô Ä¡·áÇϳª? | ±èÁ¾È (¼¼Á¾º´¿ø) |
Time | Title | Speaker |
---|---|---|
12:00-13:00 | Luncheon symposium | ¡¡ |
12:00-12:20 | Hypertension treatment options considering BP Variability | ±Ç¼º¿í (ÀÎÁ¦ÀÇ´ë) |
12:20-12:40 | Beta-blockers in the management of hypertension with real world practice | ÀÌÀ¯È« (ûÁÖÇѱ¹º´¿ø) |
13:00-13:40 | State of the Art : Çѱ¹ ½ÉÃÊÀ½ÆÄÀÇ ¾îÁ¦¿Í ¿À´Ã, ±×¸®°í ¹Ì·¡ | Á¤³²½Ä (Çʸ޵𽺳»°ú) |
13:40-15:10 | Session IV. Àü½ÅÁúȯ°ú ½ÉÀå | ÁÂÀå: ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ³ëÅÂÈ£ °¨»ç °æ±âµµ³»°úÀÇ»çȸ Àå¿õ±â ȸÀå |
13:40-14:10 | Åëdz, ¿ä»ê°ú ½ÉÀå | ¼ÛÁ¤¼ö (Áß¾ÓÀÇ´ë) |
14:10-14:40 | ½ÉÀåÁúȯ Áø´Ü¿¡ À¯¿ëÇÑ serologic marker | ±èÇü¼· (°è¸íÀÇ´ë) |
14:40-15:00 | ¼ö¸éÀå¾Ö¿Í ½ÉÇ÷°üÁúȯ | °±â¿î (À»ÁöÀÇ´ë) |
15:00-15:20 | °¡½¿ÀÌ ´ä´äÇÑ È¯ÀÚ, ¾ðÁ¦ ¾î¶»°Ô Á¤½Å°Ç°ÀÇÇаú·Î Àü¿ø ½Ãų±î? | ½Å¿µÃ¶ (¼º±Õ°üÀÇ´ë) |